Kamada, which provides plasma-derived protein therapeutics mostly in Israel and the US, raised $52 million by offering 5.6 million shares at $9.25. Kamada plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on 1/24/2013....read more
The following IPOs are expected to price this week:
Epizyme (EPZM), a biotech developing therapeutics for patients with genetically defined cancers, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the ...read more
Exactly one year after Facebook priced its ill-fated IPO, two fast-growing technology companies, Marketo (MKTO) and Tableau (DATA), surged on their first days of trading. Marketo, a marketing software company, jumped 78% on Friday in the best first-day...read more
US IPO Recap: May ends with 30 pricings, two billion-dollar deals set for June
30 IPO...read more
Kamada prices IPO at $9.25, raising $52 million
Kamada, which provides plasma-derived protein therapeutics mostly in Israel and the US, raised $52 million by offering 5.6 million shares at $9.25. Kamada plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on 1/24/2013....read more
2 US IPOs planned for the week of May 27
The following IPOs are expected to price this week: Epizyme (EPZM), a biotech developing therapeutics for patients with genetically defined cancers, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the ...read more
US IPO Recap: Marketo and Tableau soar, May calendar stays full
Exactly one year after Facebook priced its ill-fated IPO, two fast-growing technology companies, Marketo (MKTO) and Tableau (DATA), surged on their first days of trading. Marketo, a marketing software company, jumped 78% on Friday in the best first-day...read more